MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer

被引:11
|
作者
Romeo, Valeria [1 ]
Cuocolo, Renato [2 ,3 ]
Sanduzzi, Luca [1 ]
Carpentiero, Vincenzo [1 ]
Caruso, Martina [1 ]
Lama, Beatrice [1 ]
Garifalos, Dimitri [1 ]
Stanzione, Arnaldo [1 ]
Maurea, Simone [1 ]
Brunetti, Arturo [1 ]
机构
[1] Univ Naples Federico II, Dept Adv Biomed Sci, I-80131 Naples, Italy
[2] Univ Salerno, Dept Med Surg & Dent, I-84084 Baronissi, Italy
[3] Univ Naples Federico II, Dept Elect Engn & Informat Technol, Augmented Real Hlth Monitoring Lab ARHeMLab, I-80131 Naples, Italy
关键词
radiomics; oncotype DX; breast cancer; machine learning; neoadjuvant chemotherapy; magnetic resonance; recurrence score; CHEMOTHERAPY; TAMOXIFEN; FEATURES; RISK;
D O I
10.3390/cancers15061840
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The preoperative definition of the Oncotype DX recurrence score would be critical to identify breast cancer patients who could benefit from chemotherapy before surgery. In this work, we built a machine learning model applied to DCE-MRI images of a publicly available dataset to predict the Oncotype DX score in patients with breast cancer. As a result, the model achieved an accuracy of 60% in the training set and 63% (AUC = 0.66) in the test set. Our findings support the feasibility of radiomics and machine learning for the prediction of prognostic data in breast cancer, encouraging further, preferably multicenter, investigations to further improve the performance of the model and assess its generalizability. Aim: To non-invasively predict Oncotype DX recurrence scores (ODXRS) in patients with ER+ HER2- invasive breast cancer (IBC) using dynamic contrast-enhanced (DCE) MRI-derived radiomics features extracted from primary tumor lesions and a ML algorithm. Materials and Methods: Pre-operative DCE-MRI of patients with IBC, no history of neoadjuvant therapy prior to MRI, and for which the ODXRS was available, were retrospectively selected from a public dataset. ODXRS was obtained on histological tumor samples and considered as positive if greater than 16 and 26 in patients aged under and over 50 years, respectively. Tumor lesions were manually annotated by three independent operators on DCE-MRI images through 3D ROIs positioning. Radiomic features were therefore extracted and selected using multistep feature selection process. A logistic regression ML classifier was then employed for the prediction of ODXRS. Results: 248 patients were included, of which 87 with positive ODXRS. 166 (66%) patients were grouped in the training set, while 82 (33%) in the test set. A total of 1288 features was extracted. Of these, 1244 were excluded as 771, 82 and 391 were excluded as not stable (n = 771), not variant (n = 82), and highly intercorrelated (n = 391), respectively. After the use of recursive feature elimination with logistic regression estimator and polynomial transformation, 92 features were finally selected. In the training set, the logistic regression classifier obtained an overall mean accuracy of 60%. In the test set, the accuracy of the ML classifier was 63%, with a sensitivity of 80%, specificity of 43%, and AUC of 66%. Conclusions: Radiomics and ML applied to pre-operative DCE-MRI in patients with IBC showed promises for the non-invasive prediction of ODXRS, aiding in selecting patients who will benefit from NAC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Prediction of Oncotype DX recurrence score in breast cancer by integration of DCE-MRI radiomics and clinicopathologic data
    Cui, Yajing
    Fan, Ming
    Peng, Weijun
    Liu, Li
    Bai, Qianming
    Li, Lihua
    MEDICAL IMAGING 2021: IMAGING INFORMATICS FOR HEALTHCARE, RESEARCH, AND APPLICATIONS, 2021, 11601
  • [2] Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database
    Roberts, Megan C.
    Miller, Dave P.
    Shak, Steven
    Petkov, Valentina I.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 303 - 310
  • [3] Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
    Fried, Georgeta
    Moskovitz, Mor
    SPRINGERPLUS, 2014, 3 : 1 - 8
  • [4] Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
    Dodson, Andrew
    Okonji, David
    Assersohn, Laura
    Rigg, Anne
    Sheri, Amna
    Turner, Nick
    Smith, Ian
    Parton, Marina
    Dowsett, Mitch
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 249 - 258
  • [5] A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models
    Saha, Ashirbani
    Harowicz, Michael R.
    Wang, Weiyao
    Mazurowski, Maciej A.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (05) : 799 - 807
  • [6] Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer Cases
    Nguyen, Michaela T.
    Stessin, Alexander
    Nagar, Himanshu
    D'Alfonso, Timothy M.
    Chen, Zhengming
    Cigler, Tessa
    Hayes, Mary Kay
    Shin, Sandra J.
    CLINICAL BREAST CANCER, 2014, 14 (03) : 182 - 190
  • [7] Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results
    Kamaljeet Singh
    Xin He
    Elizabeth T. Kalife
    Shahrzad Ehdaivand
    Yihong Wang
    C. James Sung
    Breast Cancer Research and Treatment, 2018, 168 : 29 - 34
  • [8] An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer
    Felts, Jesse L.
    Zhu, Junjia
    Han, Bing
    Smith, Stanley J.
    Truica, Cristina I.
    BREAST JOURNAL, 2017, 23 (06) : 677 - 686
  • [9] The Warwick Experience of the Oncotype DX® Breast Recurrence Score® Assay as a Predictor of Chemotherapy Administration
    Khan, Mashuk Alam
    Henderson, Laura
    Clarke, Dayalan
    Harries, Simon
    Jones, Lucie
    BREAST CARE, 2018, 13 (05) : 369 - 372
  • [10] Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations
    Lewin, R.
    Sulkes, A.
    Shochat, T.
    Tsoref, D.
    Rizel, S.
    Liebermann, N.
    Hendler, D.
    Neiman, V.
    Ben-Aharon, I.
    Friedman, E.
    Paluch-Shimon, S.
    Margel, D.
    Kedar, I.
    Yerushalmi, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (03) : 511 - 516